EU panel gives positive opinion on once-weekly TransCon CNP for treating achondroplasia in children

The European Medicines Agency's CHMP has recommended marketing authorization for Ascendis Pharma's once-weekly TransCon CNP (navepegritide) to treat achondroplasia in children aged two and older with open growth plates. This positive opinion follows clinical trials showing the drug's effectiveness and safety. The final decision by the European Commission is expected in Q4 2026, with a planned launch in Germany in Q1 2027 under the brand name YUVIWEL. TransCon CNP is already approved in the U.S. and offers continuous exposure to active CNP to counteract the genetic disorder's effects on bone growth and other complications.

Ascendis Pharma shares trade at USD 226.91 on Pluang as of Oct 16, 2026, 19:42 WIB, showing a slight 0.13% gain for the day. The stock's market cap stands at $14.90 billion with a strong buy interest of 88% among Pluang users. This positive momentum comes ahead of the European Commission's final decision expected in Q4 2026.